Et åbent, enkeltarmsstudie til evaluering af farmakokinetik og sikkerhed af subkutan sonelokimab hos unge med moderat til svær Hidradenitis Suppurativa (VELA-TEEN)
Et åbent, enkeltarmsstudie til evaluering af farmakokinetikken og sikkerheden af subkutan sonelokimab hos unge i alderen ≥12 til ≤17 år på undersøgelsestidspunktet inklusion med aktiv moderat til svær Hidradenitis Suppurativa
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Arkansas
-
North Little Rock, Arkansas, Forenede Stater, 72117
- Clinical Site
-
-
California
-
Stanford, California, Forenede Stater, 94304
- Clinical Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Clinical Site
-
-
Florida
-
Hollywood, Florida, Forenede Stater, 33201
- Clinical Site
-
Miami, Florida, Forenede Stater, 33136
- Clinical Site
-
-
Georgia
-
Macon, Georgia, Forenede Stater, 31217
- Clinical Site
-
Sandy Springs, Georgia, Forenede Stater, 30328
- Clinical Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Clinical Site
-
-
Indiana
-
Columbus, Indiana, Forenede Stater, 47201
- Clinical Site
-
-
Kentucky
-
Murray, Kentucky, Forenede Stater, 42071
- Clinical Site
-
-
Michigan
-
Waterford, Michigan, Forenede Stater, 48328
- Clinical Site
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58103
- Clinical Site
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Clinical Site
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75246
- Clinical Site
-
Dallas, Texas, Forenede Stater, 75390-8575
- Clinical Site
-
San Antonio, Texas, Forenede Stater, 78218
- Clinical Site
-
-
Virginia
-
Norfolk, Virginia, Forenede Stater, 23502
- Clinical Site
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Clinical Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participants must be between ≥12 and ≤17 years of age at the time of signing the informed consent.
- Participants who are diagnosed with HS as determined by the investigator and have a history of signs and symptoms of HS for ≥6 months before signing the informed consent.
- Participants who have moderate to severe HS as determined by the refined Hurley staging (Stages IB and IC, IIB and IIC, and III).
- Participants who have had an inadequate response to appropriate systemic antibiotics for treatment of HS .
- Participants must be up to date with age-appropriate vaccine requirements 8 weeks prior to entry in the study.
- Participants with a body weight of ≥ 40 kg.
Exclusion Criteria:
- Participants with a known hypersensitivity to sonelokimab or any of its excipients.
- Participants with a draining fistula count of ≥20 at the Screening Visit.
- Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
- Participants with underlying conditions that, in the opinion of the investigator, potentially compromise the participant and/or places the participant at unacceptable risk.
- Participants who have history or concurrent clinically significant medical conditions or any other reason, including any physical, psychological, or psychiatric condition, that in the opinion of the investigator would compromise the safety or interfere with participation in the study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk.
- Participants with any other skin disease or other medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
- Participants with a confirmed or suspected diagnosis of inflammatory bowel disease.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: sonelokimab
Subjects will receive sonelokimab 120mg subcutaneously (SC) as an induction regimen of 4 doses, followed by sonelokimab SC every 4 weeks maintenance dose starting at Week 8 |
Open label |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetics (PK) of sonelokimab in adolescents
Tidsramme: Week 24
|
PK (trough concentrations) of sonelokimab over 24 weeks of treatment |
Week 24
|
|
Adverse events (AEs) following treatment with sonelokimab in adolescents
Tidsramme: Week 24
|
Incidence, relatedness, severity and seriousness of all AEs over 24 weeks of treatment from baseline |
Week 24
|
|
Discontinuation of sonelokimab treatment due to AEs
Tidsramme: Week 24
|
Number of participants discontinued from sonelokimab treatment due to AE over 24 weeks of treatment from baseline |
Week 24
|
|
Clinically significant changes in clinical laboratory parameters
Tidsramme: Week 24
|
Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline |
Week 24
|
|
Clinically significant changes in vital signs
Tidsramme: Week 24
|
Number of participants with clinically significant changes in vital signs from baseline |
Week 24
|
|
Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervals
Tidsramme: Week 24
|
Number of participants with clinically significant changes in 12-lead ECG intervals from baseline |
Week 24
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hidradenitis Suppurativa Clinical Response (HiSCR)75
Tidsramme: Week 24
|
Percentage of participants achieving a HiSCR75 response over time |
Week 24
|
|
Hidradenitis Suppurativa Clinical Response (HiSCR) 50
Tidsramme: Week 24
|
Percentage of participants achieving a HiSCR50 response over time |
Week 24
|
|
International Hidradenitis Suppurativa Severity Score System (IHS4)
Tidsramme: Week 24
|
Absolute change in IHS4 score over time |
Week 24
|
|
Children's Dermatology Life Quality Index (CDLQI)
Tidsramme: Week 24
|
Percentage of participants achieving a CDLQI total reduction of ≥2.5 over time among participants with a baseline CDLQI ≥2.5 |
Week 24
|
|
Numerical Rating Scale (NRS) 30
Tidsramme: Week 24
|
Percentage of participants achieving a ≥30% reduction and a ≥2-unit reduction over time in the NRS30 for pain in PGA among participants with a baseline NRS ≥3 |
Week 24
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Infektioner
- Betændelse
- Bakterielle infektioner
- Bakterielle infektioner og mykoser
- Hudsygdomme, smitsom
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Hidradenitis Suppurativa
- Hidradenitis
- Hudsygdomme
- Hudsygdomme, bakteriel
- Svedkirtelsygdomme
- Suppuration
- Sonelokimab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- M1095-HS-304
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .